ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

AN OBSERVATIONAL STUDY TO ASSESS SUSTAINED VIROLOGIC RESPONSE (SVR) AFTER THE TREATMENT WITH DACLATASVIR IN ADDITION WITH SOFOSBUVIR IN HCV GENOTYPE 3a DISEASE

Dr Syeda Rubbab Naqvi, Dr Muhammad Awais, Dr Hidayatullah

Study aim: We held this study to conclude sustained virologic response (SVR) after the treatment with Daclatasvir in addition with sofosbuvir regardless of liver cirrhosis or any previous treatment history. Study design: Open label observational study. Place and duration: This study was conducted at mayo hospital, Lahore for the duration of one year starting from May, 2018 to March, 2019. Material and methodology: We included a total number of 125 patients in our study who were having genotype 3a hepatitis C virus regardless of previous treatment history or presence of cirrhosis. Daclatasvir (60mg) in addition with sofosbuvir (400mg) on daily basis for the duration of 03 months were prescribed for treatment of those patients who were without cirrhosis. Whereas, daclatasvir (60mg) in addition with sofosbuvir (400mg) with ribavirin according to the weight of the patients were given to those patients who were either with treatment history or having cirrhosis. Dosage was prescribed on daily bases for the duration of 06 months. Use SPSS 21 for analysis of collected data. Results: There were total 125 patients included in our study. Gender distribution as male and female was as 42 (33.60%) and 83 (66.40%) respectively. 124 (99.2%) patients achieved initial virological responses and end treatment responses. SVR24 (sustained virologic response at week 24) for 80.8% (101) patients among which there were 53 patients without cirrhosis and 48 patients were having cirrhosis. 95% (96) patients out of 101 achieved SVR24 (sustained virologic response at week 24). According to the findings of our study, compared to patients who underwent treatment before our study and those who were having cirrhosis, virological response was found much better in patients without cirrhosis and in treatment naive patients. Conclusion: At the end of present study we concluded that in patients with chronic hepatitis C genotype 3a disease combination of daclatasvir with sofosbuvir is very effective. Key Words: Sofosbuvir, Genotype 3a, Chronic hepatitis C, Daclatasvir, SVR24 (sustained virologic response at week 24).

FULL TEXT